Koru Medical Systems, Inc. (KRMD) — SEC Filings

Koru Medical Systems, Inc. (KRMD) — 25 SEC filings. Latest: 8-K (Nov 25, 2025). Includes 10 8-K, 6 10-Q, 3 SC 13G/A.

View Koru Medical Systems, Inc. on SEC EDGAR

Overview

Koru Medical Systems, Inc. (KRMD) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Nov 25, 2025: KORU Medical Systems, Inc. entered into a Material Definitive Agreement on November 19, 2025. The filing also includes financial statements and exhibits related to this agreement. The company, formerly known as REPRO MED SYSTEMS INC, is incorporated in Delaware and headquartered in Mahwah, NJ.

Sentiment Summary

Across 25 filings, the sentiment breakdown is: 1 bearish, 22 neutral, 2 mixed. The dominant filing sentiment for Koru Medical Systems, Inc. is neutral.

Filing Type Overview

Koru Medical Systems, Inc. (KRMD) has filed 10 8-K, 6 10-Q, 2 10-K, 3 SC 13G/A, 2 SC 13G, 1 DEF 14A, 1 SC 13D/A with the SEC between Jan 2024 to Nov 2025.

Filings by Year

2025 · 2024

Recent SEC Filings (25)

Koru Medical Systems, Inc. SEC Filing History
DateFormDescriptionRisk
Nov 25, 20258-KKORU Medical Systems Enters Material Definitive Agreementmedium
Nov 12, 202510-QKORU Medical Narrows Losses on Strong International Revenue Growthmedium
Aug 6, 202510-QKORU Medical's Q2 Loss Widens to $3.5M Amid Revenue Diphigh
May 15, 20258-KKORU Medical Systems Files 8-K on Shareholder Vote Matterslow
May 7, 202510-QKORU Medical Systems Files Q1 2025 10-Q Reportlow
Apr 7, 20258-KKORU Medical Systems Announces Board and Executive Changesmedium
Apr 4, 20258-KKORU Medical Systems Files 8-K for Material Agreementmedium
Mar 12, 202510-KKORU Medical Systems Files 2024 10-Kmedium
Jan 13, 20258-KKORU Medical Systems Files 8-K on Financialslow
Nov 14, 2024SC 13G/ASC 13G/A Filing
Nov 13, 202410-QKORU Medical Systems Files Q3 2024 10-Q Reportmedium
Nov 13, 2024SC 13G/ASC 13G/A Filing
Aug 21, 20248-KKORU Medical Systems Announces Board and Executive Changesmedium
Aug 7, 202410-QKORU Medical Systems Files Q2 2024 10-Q Reportlow
Jul 24, 20248-KKORU Medical Systems Announces Director Changes and Officer Appointmentsmedium
Jun 3, 20248-KKORU Medical Systems Changes Auditorsmedium
May 23, 2024SC 13GSC 13G Filing
May 14, 20248-KKORU Medical Systems Reports on Shareholder Votelow
May 1, 202410-QKORU Medical Systems, Inc. Files 10-Q for Period Ending March 31, 2024low
Apr 11, 20248-KKORU Medical Systems Files 8-Klow

Risk Profile

Risk Assessment: Of KRMD's 19 recent filings, 1 were flagged as high-risk, 10 as medium-risk, and 8 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.

Financial Highlights

Koru Medical Systems, Inc. Financial Summary (10-Q, Nov 12, 2025)
MetricValue
Revenue$10,402,163
Net Income-$777,966
EPS-$0.02
Cash Position$8,464,019
Total Assets$27,103,526
Total Debt$10,638,701

Key Executives

  • United States
  • Canada
  • Michael J. O'Hanlon
  • David L. Johnson

Industry Context

KORU Medical Systems operates in the medical device sector, specifically focusing on innovative solutions for vascular access. The industry is characterized by rapid technological advancements, stringent regulatory requirements, and a competitive landscape with both established players and emerging companies. Growth is often driven by the development of minimally invasive technologies and expanding access to healthcare globally.

Top Tags

10-Q (4) · financials (4) · filing (2) · Medical Devices (2) · 10-Q Filing (2) · shareholder-vote (2) · corporate-governance (2) · quarterly-report (2) · executive-compensation (2) · 10-K (2)

Key Numbers

Koru Medical Systems, Inc. Key Metrics
MetricValueContext
SEC File Number001-39086Identifies the company's filings with the SEC.
IRS Employer Identification No.13-3044880Company's tax identification number.
Net Revenues (Q3 2025)$10,402,163Increased by 27.17% from $8,179,977 in Q3 2024
Net Revenues (YTD Q3 2025)$30,232,038Increased by 21.87% from $24,807,864 in YTD Q3 2024
Net Loss (Q3 2025)$777,966Improved from $1,580,817 net loss in Q3 2024
Net Loss (YTD Q3 2025)$2,151,070Improved from $4,505,490 net loss in YTD Q3 2024
International Revenue (Q3 2025)$3,695,524Increased by 219.14% from $1,157,166 in Q3 2024
Cash and Cash Equivalents (Sept 30, 2025)$8,464,019Decreased from $9,580,947 at Dec 31, 2024
Research and Development (Q3 2025)$933,107Decreased from $1,533,845 in Q3 2024
Net Loss (Q2 2025)$3.5MIncreased from $2.1M in Q2 2024, indicating worsening profitability.
Revenue (Q2 2025)$12.8MDecreased from $13.1M in Q2 2024, a 2.3% decline.
Net Loss (Six Months 2025)$7.2MIncreased from $4.5M in the prior-year period, showing sustained losses.
Cash and Cash Equivalents (June 30, 2025)$12.1MDecreased from $15.3M at December 31, 2024, highlighting cash burn.
Total Assets (June 30, 2025)$65.2MDecreased from $68.5M at December 31, 2024, reflecting asset reduction.
Revenue Decline (Q2 2025 vs. Q2 2024)2.3%Indicates a contraction in sales for the quarter.

Forward-Looking Statements

  • {"claim":"KORU Medical Systems, Inc. stock may experience short-term selling pressure due to the disclosed reduction in institutional ownership.","entity":"KORU Medical Systems, Inc.","targetDate":"Q1 2024","confidence":"medium"}

Related Companies

KORU

Frequently Asked Questions

What are the latest SEC filings for Koru Medical Systems, Inc. (KRMD)?

Koru Medical Systems, Inc. has 25 recent SEC filings from Jan 2024 to Nov 2025, including 10 8-K, 6 10-Q, 3 SC 13G/A. Each filing includes an AI-generated plain-English summary.

What is the overall sentiment of KRMD filings?

Across 25 filings, the sentiment breakdown is: 1 bearish, 22 neutral, 2 mixed. The dominant sentiment is neutral.

Where can I find Koru Medical Systems, Inc. SEC filings explained simply?

ReadTheFiling provides AI-powered plain-English summaries of all Koru Medical Systems, Inc. (KRMD) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.

What are the key financial highlights for Koru Medical Systems, Inc.?

Key financial highlights from Koru Medical Systems, Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.

What is the investment thesis for KRMD?

The investment thesis for KRMD includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.

Who are the key executives at Koru Medical Systems, Inc.?

Key executives identified across Koru Medical Systems, Inc.'s filings include United States, Canada, Michael J. O'Hanlon, David L. Johnson.

What are the main risk factors for Koru Medical Systems, Inc. stock?

Of KRMD's 19 assessed filings, 1 were flagged high-risk, 10 medium-risk, and 8 low-risk.

What are recent predictions and forward guidance from Koru Medical Systems, Inc.?

Recent forward-looking statements from Koru Medical Systems, Inc. include guidance on {"claim":"KORU Medical Systems, Inc. stock may experience short-term selling pressure due to the disclosed reduction in .

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.